ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Two-Week chemo blast be just as good as three for AML?
Disease control Not yet recruitingThis study tests whether a two-week course of the VA-CAG chemotherapy works as well as the usual three-week course for adults newly diagnosed with acute myeloid leukemia (AML). About 110 participants will be randomly assigned to one of the two schedules. The goal is to see if the…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy aims to boost leukemia remission in seniors
Disease control Not yet recruitingThis Phase 3 trial will test whether adding homoharringtonine to the standard two-drug regimen of venetoclax and azacitidine improves remission rates in adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). About 308 participants will be randomly assigned to receiv…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for elderly AML patients: drug combo aims to control disease without harsh chemo
Disease control Not yet recruitingThis study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor (G-CSF) in 61 older or frail adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if thi…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for AML patients who fail standard therapy: experimental combo trial launches
Disease control Not yet recruitingThis phase 2 trial tests a new combination of drugs—lisafotoclax, decitabine, and homoharringtonine—in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate the standard venetoclax/azacitidine regimen. The goal is to see if this new mix…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for AML: Three-Drug combo aims to boost remission
Disease control Not yet recruitingThis Phase 3 trial tests a new combination of drugs (venetoclax, azacitidine, and a liposomal form of mitoxantrone) against the standard therapy for adults newly diagnosed with acute myeloid leukemia (AML). The study will enroll 204 people aged 18-65 to see if the new combo leads…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising Three-Drug cocktail targets Hard-to-Treat leukemia
Disease control Not yet recruitingThis study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—in people with acute myeloid leukemia (AML) who are either newly diagnosed and unable to tolerate standard chemotherapy, or whose cancer has returned or not responded to treatment. The trial ha…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill combo aims to tame tough leukemia
Disease control Not yet recruitingThis study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 ad…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hard-to-treat leukemia: three-drug combo targets relapsed AML
Disease control Not yet recruitingThis study tests a combination of three drugs (cladribine, low dose cytarabine, and venetoclax) in 24 adults with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment, especially after a venetoclax-based regimen. The goal is to see if this combinatio…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New blood test could personalize AML treatment
Diagnosis Not yet recruitingThis study tests a new blood test (5hmC) to see if it can help doctors choose between two standard treatments for acute myeloid leukemia (AML): a milder drug (hypomethylating agent) or strong chemotherapy. About 112 newly diagnosed adults will have their blood tested after initia…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
Massive data pool aims to crack childhood Leukemia's toughest cases
Knowledge-focused Not yet recruitingThis study will gather and combine medical and genetic data from 2,000 children with acute myeloid leukemia (AML) across France. The goal is to find hidden patterns that predict which patients are most likely to relapse. By creating a large, shared database, researchers hope to i…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:37 UTC